Results 111 to 120 of about 365,110 (263)

IGF2 knockout reduces but does not abolish osteosarcoma growth in vitro and in vivo

FEBS Open Bio, EarlyView.
To test whether endogenous IGF2 promotes osteosarcoma growth, IGF2 was knocked out in Saos2 cells via CRISPR‐Cas9. KO cells showed reduced proliferation in vitro, and knockout xenografts in mice reached only ~25% of wild‐type tumor volume. Insulin‐like growth factor 2 (IGF2) is implicated in osteosarcoma, but direct functional evidence of its role is ...
Shun Yao, Marco Archetti
wiley   +1 more source

Commentary: Novel Cell Culture Paradigm Prolongs Mouse Corneal Epithelial Cell Proliferative Activity In Vitro and In Vivo

Frontiers in Cell and Developmental Biology, 2022
Xiuna Ji, Mingyue Zheng, Tingjun Fan, Bin Xu   +3 more
doaj   +1 more source

The effects of a magnetic IronQ complex on endothelial progenitor cells expansion in vitro

Journal of Associated Medical Sciences, 2016
Introduction: In vitro proliferation and expansion of endothelial progenitor cells play important roles in the cell-based therapies for patient with acute myocardial infarction or ischemic heart disease.
Jiraporn Kantapan, Nathupakorn Dechsupa
doaj  

Selective elimination of quiescent cancer cells by dequalinium chloride via ROS‐mediated ferroptosis

FEBS Open Bio, EarlyView.
Dequalinium chloride (DQ) selectively eliminates quiescent cancer cells (QCCs) by amplifying mitochondrial ROS. QCCs exhibit elevated basal ROS and limited redox‐buffering capacity, making them vulnerable to further ROS increases. DQ‐induced ROS exceeds the tolerance threshold, triggering lipid peroxidation and ferroptosis, whereas proliferating cells ...
Kotaro Miyamoto, Shiori Sakai, Minori Endo, Terigele, Mizuho Niibori, Taiki Morita, Yu Goto, Arisa Yoshida, Tomohiro Tanaka, Ning Lin, Takahiro Kuchimaru, Hiroyuki Nakamura, Masahiro Inoue, Shinae Kizaka‐Kondoh, Tetsuya Kadonosono   +14 more
wiley   +1 more source

Simultaneous Identification of Functional Antigen-Specific CD8⁺ and CD4⁺ Cells after In Vitro Expansion Using Elongated Peptides. [PDF]

Cells, 2022
Schuhmacher J, Kleemann L, Richardson JR, Rusch E, Rammensee HG, Gouttefangeas C.   +5 more
europepmc   +1 more source

TRPML1 agonist ML‐SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux

FEBS Open Bio, EarlyView.
TGF‐β1 stimulation downregulates lysosomal channel TRPML1 in pulmonary fibroblasts. The TRPML1 agonist ML‐SA5 suppressed fibroblast‐to‐myofibroblast activation and collagen production. Mechanistically, ML‐SA5 inhibited mTOR phosphorylation, restored autophagic flux, and its effects were enhanced by rapamycin (mTOR inhibitor) and reversed by MHY1485 ...
Jiatong Yao, Xiaoting Kang, Lulu Meng, Shaoxuan Zhang, Qiujie Li, Jinyu Zhou, Mengyue Xue, Chu Li, Hua Zhu, Pengzhou Hang, Jing Zhao   +10 more
wiley   +1 more source

Cord blood-derived V_δ2⁺ and V_δ2^- T cells acquire differential cell state compositions upon in vitro expansion. [PDF]

Sci Adv, 2023
Ng JWK, Tan KW, Guo DY, Lai JJH, Fan X, Poon Z, Lim TH, Lim AST, Lim TKH, Hwang WYK, Li S, Eaves CJ, Goh YT, Cheung AMS.   +13 more
europepmc   +1 more source

In vitro generation of regulatory T cells: A challenging tool for studying immune aging in humans

FEBS Open Bio, EarlyView.
In vitro induction of human regulatory T cells using standard protocols generates suppressive, Foxp3‐expressing CD4+ T cells independently of TGF‐β supplementation and donor age. Regulatory T (Treg) cells play a key role in immune tolerance and homeostasis.
Lynn Muller, Jana Bleher, Birgit Weinberger, Lourdes Rocamora‐Reverte   +3 more
wiley   +1 more source

In Vitro Expansion of Vδ1+ T Cells from Cord Blood by Using Artificial Antigen-Presenting Cells and Anti-CD3 Antibody. [PDF]

Vaccines (Basel), 2023
Hur G, Choi H, Lee Y, Sohn HJ, Kim SY, Kim TG.   +5 more
europepmc   +1 more source

Unraveling 4‐Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw, Karishma Randhave, Ekta Anand, Ziang (Debbie) Song, Wangzhen Shen, Jing‐Qiong Kang   +5 more
wiley   +1 more source